APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Antivirals

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global HIV Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173998770327 December 2025185 pages

Choose your research edition.

Industry ResearchHIV Antivirals Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Antivirals Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal HIV Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Antivirals Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Antivirals Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global HIV Antivirals market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for HIV Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV Antivirals include Teva Pharmaceuticals, Merck & Co., Roche, Gilead Sciences, AbbVie, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals) and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV Antivirals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Antivirals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Antivirals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV Antivirals market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV Antivirals Segment by Company

Teva Pharmaceuticals

Merck & Co.

Roche

Gilead Sciences

AbbVie

ViiV Healthcare

Johnson & Johnson (Janssen Pharmaceuticals)

Bristol-Myers Squibb

HIV Antivirals Segment by Type

Protease Inhibitors (Pls)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)

Fixed Dose Combinations (FDCs)

Nucleoside Reverse Transcriptase lnhibitors (NRTls)

Entry Inhibitors -CCR5 co-receptor antagonist

Integrase Strand Transfer Inhibitors (lNSTls)

Others

HIV Antivirals Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

HIV Antivirals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Antivirals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV Antivirals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of HIV Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of HIV Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. HIV Antivirals Industry Trends Table 2. HIV Antivirals Industry Drivers Table 3. HIV Antivirals Industry Opportunities and Challenges Table 4. HIV Antivirals Industry Restraints Table 5. Global HIV Antivirals Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global HIV Antivirals Revenue Market Share by Manufacturers (2021-2026) Table 7. Global HIV Antivirals Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global HIV Antivirals Sales Market Share by Manufacturers Table 9. Global HIV Antivirals Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global HIV Antivirals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global HIV Antivirals Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global HIV Antivirals Manufacturers, Product Type & Application Table 13. Global HIV Antivirals Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV Antivirals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Protease Inhibitors (Pls) Table 17. Major Manufacturers of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Table 18. Major Manufacturers of Fixed Dose Combinations (FDCs) Table 19. Major Manufacturers of Nucleoside Reverse Transcriptase lnhibitors (NRTls) Table 20. Major Manufacturers of Entry Inhibitors -CCR5 co-receptor antagonist Table 21. Major Manufacturers of Integrase Strand Transfer Inhibitors (lNSTls) Table 22. Major Manufacturers of Others Table 23. Global HIV Antivirals Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global HIV Antivirals Sales by Type (2021-2026) & (K Units) Table 25. Global HIV Antivirals Sales by Type (2027-2032) & (K Units) Table 26. Global HIV Antivirals Sales Market Share by Type (2021-2026) Table 27. Global HIV Antivirals Sales Market Share by Type (2027-2032) Table 28. Global HIV Antivirals Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global HIV Antivirals Revenue by Type (2021-2026) & (K Units) Table 30. Global HIV Antivirals Revenue by Type (2027-2032) & (K Units) Table 31. Global HIV Antivirals Revenue Market Share by Type (2021-2026) Table 32. Global HIV Antivirals Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Hospital Pharmacies Table 34. Major Manufacturers of Retail Pharmacies Table 35. Major Manufacturers of Online Pharmacies Table 36. Global HIV Antivirals Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global HIV Antivirals Sales by Application (2021-2026) & (K Units) Table 38. Global HIV Antivirals Sales by Application (2027-2032) & (K Units) Table 39. Global HIV Antivirals Sales Market Share by Application (2021-2026) Table 40. Global HIV Antivirals Sales Market Share by Application (2027-2032) Table 41. Global HIV Antivirals Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global HIV Antivirals Revenue by Application (2021-2026) & (K Units) Table 43. Global HIV Antivirals Revenue by Application (2027-2032) & (K Units) Table 44. Global HIV Antivirals Revenue Market Share by Application (2021-2026) Table 45. Global HIV Antivirals Revenue Market Share by Application (2027-2032) Table 46. Global HIV Antivirals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global HIV Antivirals Sales by Region (2021-2026) & (K Units) Table 48. Global HIV Antivirals Sales Market Share by Region (2021-2026) Table 49. Global HIV Antivirals Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global HIV Antivirals Sales Forecasted Market Share by Region (2027-2032) Table 51. North America HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 53. North America HIV Antivirals Sales by Country (2027-2032) & (K Units) Table 54. Europe HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 56. Europe HIV Antivirals Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific HIV Antivirals Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa HIV Antivirals Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa HIV Antivirals Sales by Country (2027-2032) & (K Units) Table 63. Global HIV Antivirals Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global HIV Antivirals Revenue by Region (2021-2026) & (US$ Million) Table 65. Global HIV Antivirals Revenue by Region (2027-2032) & (US$ Million) Table 66. Global HIV Antivirals Revenue Market Share by Region (2021-2026) Table 67. Global HIV Antivirals Revenue Market Share by Region (2027-2032) Table 68. Teva Pharmaceuticals Company Information Table 69. Teva Pharmaceuticals Business Overview Table 70. Teva Pharmaceuticals HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Teva Pharmaceuticals HIV Antivirals Product Portfolio Table 72. Teva Pharmaceuticals Recent Development Table 73. Merck & Co. Company Information Table 74. Merck & Co. Business Overview Table 75. Merck & Co. HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck & Co. HIV Antivirals Product Portfolio Table 77. Merck & Co. Recent Development Table 78. Roche Company Information Table 79. Roche Business Overview Table 80. Roche HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Roche HIV Antivirals Product Portfolio Table 82. Roche Recent Development Table 83. Gilead Sciences Company Information Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Gilead Sciences HIV Antivirals Product Portfolio Table 87. Gilead Sciences Recent Development Table 88. AbbVie Company Information Table 89. AbbVie Business Overview Table 90. AbbVie HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. AbbVie HIV Antivirals Product Portfolio Table 92. AbbVie Recent Development Table 93. ViiV Healthcare Company Information Table 94. ViiV Healthcare Business Overview Table 95. ViiV Healthcare HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ViiV Healthcare HIV Antivirals Product Portfolio Table 97. ViiV Healthcare Recent Development Table 98. Johnson & Johnson (Janssen Pharmaceuticals) Company Information Table 99. Johnson & Johnson (Janssen Pharmaceuticals) Business Overview Table 100. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio Table 102. Johnson & Johnson (Janssen Pharmaceuticals) Recent Development Table 103. Bristol-Myers Squibb Company Information Table 104. Bristol-Myers Squibb Business Overview Table 105. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bristol-Myers Squibb HIV Antivirals Product Portfolio Table 107. Bristol-Myers Squibb Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. HIV Antivirals Distributors List Table 111. HIV Antivirals Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. HIV Antivirals Product Image Figure 2. Global HIV Antivirals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Antivirals Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Antivirals Sales (2021-2032) & (K Units) Figure 5. Global HIV Antivirals Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 HIV Antivirals Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Protease Inhibitors (Pls) Image Figure 9. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Image Figure 10. Fixed Dose Combinations (FDCs) Image Figure 11. Nucleoside Reverse Transcriptase lnhibitors (NRTls) Image Figure 12. Entry Inhibitors -CCR5 co-receptor antagonist Image Figure 13. Integrase Strand Transfer Inhibitors (lNSTls) Image Figure 14. Others Image Figure 15. Global HIV Antivirals Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global HIV Antivirals Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global HIV Antivirals Sales Market Share by Type (2021-2032) Figure 18. Global HIV Antivirals Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global HIV Antivirals Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global HIV Antivirals Revenue Market Share by Type (2021-2032) Figure 21. Hospital Pharmacies Image Figure 22. Retail Pharmacies Image Figure 23. Online Pharmacies Image Figure 24. Global HIV Antivirals Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global HIV Antivirals Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global HIV Antivirals Sales Market Share by Application (2021-2032) Figure 27. Global HIV Antivirals Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global HIV Antivirals Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global HIV Antivirals Revenue Market Share by Application (2021-2032) Figure 30. North America HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America HIV Antivirals Sales Market Share by Country (2021-2032) Figure 32. U.S. HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe HIV Antivirals Sales Market Share by Country (2021-2032) Figure 37. Germany HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific HIV Antivirals Sales Market Share by Country (2021-2032) Figure 44. China HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa HIV Antivirals Sales Market Share by Country (2021-2032) Figure 52. Brazil HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile HIV Antivirals Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global HIV Antivirals Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global HIV Antivirals Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America HIV Antivirals Revenue (2021-2032) & (US$ Million) Figure 63. North America HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe HIV Antivirals Revenue (2021-2032) & (US$ Million) Figure 65. Europe HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific HIV Antivirals Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa HIV Antivirals Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. HIV Antivirals Value Chain Figure 71. Manufacturing Cost Structure Figure 72. HIV Antivirals Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Protease Inhibitors (Pls)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
  • Fixed Dose Combinations (FDCs)
  • Nucleoside Reverse Transcriptase lnhibitors (NRTls)
  • Entry Inhibitors -CCR5 co-receptor antagonist
  • Integrase Strand Transfer Inhibitors (lNSTls)
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Teva Pharmaceuticals
  • Merck & Co.
  • Roche
  • Gilead Sciences
  • AbbVie
  • ViiV Healthcare
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV Antivirals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV Antivirals Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global HIV Antivirals Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global HIV Antivirals Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global HIV Antivirals Market Dynamics
  1. 2.1 HIV Antivirals Industry Trends
  2. 2.2 HIV Antivirals Industry Drivers
  3. 2.3 HIV Antivirals Industry Opportunities and Challenges
  4. 2.4 HIV Antivirals Industry Restraints
3 HIV Antivirals Market by Manufacturers
  1. 3.1 Global HIV Antivirals Revenue by Manufacturers (2021-2026)
  2. 3.2 Global HIV Antivirals Sales by Manufacturers (2021-2026)
  3. 3.3 Global HIV Antivirals Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global HIV Antivirals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV Antivirals Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global HIV Antivirals Manufacturers, Product Type & Application
  7. 3.7 Global HIV Antivirals Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV Antivirals Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV Antivirals Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV Antivirals Tier 1, Tier 2, and Tier 3
4 HIV Antivirals Market by Type
  1. 4.1 HIV Antivirals Type Introduction
  2. 4.1.1 Protease Inhibitors (Pls)
  3. 4.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
  4. 4.1.3 Fixed Dose Combinations (FDCs)
  5. 4.1.4 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
  6. 4.1.5 Entry Inhibitors -CCR5 co-receptor antagonist
  7. 4.1.6 Integrase Strand Transfer Inhibitors (lNSTls)
  8. 4.1.7 Others
  9. 4.2 Global HIV Antivirals Sales by Type
  10. 4.2.1 Global HIV Antivirals Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global HIV Antivirals Sales by Type (2021-2032)
  12. 4.2.3 Global HIV Antivirals Sales Market Share by Type (2021-2032)
  13. 4.3 Global HIV Antivirals Revenue by Type
  14. 4.3.1 Global HIV Antivirals Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global HIV Antivirals Revenue by Type (2021-2032)
  16. 4.3.3 Global HIV Antivirals Revenue Market Share by Type (2021-2032)
5 HIV Antivirals Market by Application
  1. 5.1 HIV Antivirals Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Online Pharmacies
  5. 5.2 Global HIV Antivirals Sales by Application
  6. 5.2.1 Global HIV Antivirals Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV Antivirals Sales by Application (2021-2032)
  8. 5.2.3 Global HIV Antivirals Sales Market Share by Application (2021-2032)
  9. 5.3 Global HIV Antivirals Revenue by Application
  10. 5.3.1 Global HIV Antivirals Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global HIV Antivirals Revenue by Application (2021-2032)
  12. 5.3.3 Global HIV Antivirals Revenue Market Share by Application (2021-2032)
6 Global HIV Antivirals Sales by Region
  1. 6.1 Global HIV Antivirals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Antivirals Sales by Region (2021-2032)
  3. 6.2.1 Global HIV Antivirals Sales by Region (2021-2026)
  4. 6.2.2 Global HIV Antivirals Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America HIV Antivirals Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe HIV Antivirals Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific HIV Antivirals Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa HIV Antivirals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa HIV Antivirals Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global HIV Antivirals Revenue by Region
  1. 7.1 Global HIV Antivirals Revenue by Region
  2. 7.1.1 Global HIV Antivirals Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global HIV Antivirals Revenue by Region (2021-2026)
  4. 7.1.3 Global HIV Antivirals Revenue by Region (2027-2032)
  5. 7.1.4 Global HIV Antivirals Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America HIV Antivirals Revenue (2021-2032)
  8. 7.2.2 North America HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe HIV Antivirals Revenue (2021-2032)
  11. 7.3.2 Europe HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific HIV Antivirals Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa HIV Antivirals Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa HIV Antivirals Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals HIV Antivirals Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Merck & Co.
  8. 8.2.1 Merck & Co. Company Information
  9. 8.2.2 Merck & Co. Business Overview
  10. 8.2.3 Merck & Co. HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co. HIV Antivirals Product Portfolio
  12. 8.2.5 Merck & Co. Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche HIV Antivirals Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences HIV Antivirals Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie HIV Antivirals Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 ViiV Healthcare
  32. 8.6.1 ViiV Healthcare Company Information
  33. 8.6.2 ViiV Healthcare Business Overview
  34. 8.6.3 ViiV Healthcare HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ViiV Healthcare HIV Antivirals Product Portfolio
  36. 8.6.5 ViiV Healthcare Recent Developments
  37. 8.7 Johnson & Johnson (Janssen Pharmaceuticals)
  38. 8.7.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
  39. 8.7.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
  40. 8.7.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio
  42. 8.7.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments
  43. 8.8 Bristol-Myers Squibb
  44. 8.8.1 Bristol-Myers Squibb Company Information
  45. 8.8.2 Bristol-Myers Squibb Business Overview
  46. 8.8.3 Bristol-Myers Squibb HIV Antivirals Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb HIV Antivirals Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV Antivirals Value Chain Analysis
  2. 9.1.1 HIV Antivirals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV Antivirals Production Mode & Process
  6. 9.2 HIV Antivirals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV Antivirals Distributors
  9. 9.2.3 HIV Antivirals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst